Major and minor salivary gland tumors

Critical Reviews in Oncology/Hematology

Volumn 74, Issue 2, 2010, Pages 134-148

  Guzzo, Marco ^a   Locati, Laura D ^a   Prott, Franz J ^b   Gatta, Gemma ^a   McGurk, Mark ^c   Licitra, Lisa ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Radiotherapy   (Germany)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Evidence based medicine; Review; Salivary gland tumors; Treatment

Indexed keywords

AXITINIB; BORTEZOMIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; GEFITINIB; IMATINIB; LAPATINIB; METHOTREXATE; PACLITAXEL; TRASTUZUMAB;

ANTIANDROGEN THERAPY; BENIGN TUMOR; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RELAPSE; CANCER SURGERY; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE DURATION; EXCISION; HUMAN; INFLAMMATION; INOPERABLE CANCER; IRRADIATION; METASTASIS; MINOR SALIVA GLAND; NECK DISSECTION; NEUTRON THERAPY; NUTRITION; PAROTID GLAND; PATIENT SELECTION; PROTON THERAPY; REVIEW; RISK FACTOR; SALIVARY GLAND CANCER; SALIVARY GLAND TUMOR; SWELLING; SYMPTOM; TREATMENT INDICATION; TUMOR LOCALIZATION;

ANIMALS; CARCINOMA; DIGESTIVE SYSTEM SURGICAL PROCEDURES; HUMANS; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; RECURRENCE; SALIVARY GLAND NEOPLASMS; SALIVARY GLANDS, MINOR;

EID: 77950073431     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2009.10.004     Document Type: Review

References (149)

1. WHO, World Health Organization. International statistical classification of diseases and related health problems, tenth revision, vol. 1. Geneva; 1992.
2. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer incidence in five continents, vol. VIII. IARC Scientific Publications No. 155. Lyon: IARC Press; 2002.
3. Carvalho A.L., Nishimoto I.N., Califano J.A., Kowalski L.P. Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer 2005, 114:806-816.
4. Berrino F., De A.R., Sant M., et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-1999: results of the EUROCARE-4 study. Lancet Oncol 2007, 8:773-783.
5. Horn-Ross P.L., Morrow M., Ljung B.M. Diet and the risk of salivary gland cancer. Am J Epidemiol 1997, 146:171-176.
6. Zheng W., Shu X.O., Ji B.T., Gao Y.T. Diet and other risk factors for cancer of the salivary glands: a population-based case-control study. Int J Cancer 1996, 67:194-198.
7. Schneider A.B., Lubin J., Ron E., et al. Salivary gland tumors after childhood radiation treatment for benign conditions of the head and neck: dose-response relationships. Radiat Res 1998, 149:625-630.
8. Coleman MP, Babb P, Daniecki P, et al. Cancer survival trends in England and Wales, 1971-1995: deprivation and NHS region. Studies in medical and population subjects no. 61. London: The Stationary Office. 1999.
9. Dong C., Hemminki K. Second primary neoplasms among 53 159 haematolymphoproliferative malignancy patients in Sweden, 1958-1996: a search for common mechanisms. Br J Cancer 2001, 85:997-1005.
10. Goldstein A.M., Yuen J., Tucker M.A. Second cancers after medulloblastoma: population-based results from the United States and Sweden. Cancer Causes Control 1997, 8:865-871.
11. Milan T., Pukkala E., Verkasalo P.K., et al. Subsequent primary cancers after basal-cell carcinoma: a nationwide study in Finland from 1953 to 1995. Int J Cancer 2000, 87:283-288.
12. Spitz M.R., Tilley B.C., Batsakis J.G., Gibeau J.M., Newell G.R. Risk factors for major salivary gland carcinoma. A case-comparison study. Cancer 1984, 54:1854-1859.
13. Serraino D., Boschini A., Carrieri P., et al. Cancer risk among men with, or at risk of HIV infection in southern Europe. AIDS 2000, 14:553-559.
14. Horn-Ross P.L., Ljung B.M., Morrow M. Environmental factors and the risk of salivary gland cancer. Epidemiology 1997, 8:414-419.
15. Swanson G.M., Burns P.B. Cancers of the salivary gland: workplace risks among women and men. Ann Epidemiol 1997, 7:369-374.
16. Barnes L., Eveson J.W., Reichart P., Sidransky D. World Health Organization classification of tumours. Pathology and genetics of head and neck tumours 2005, IARC Press, Lyon, p. 254-8.
17. Locati L.D., Losa M., Perrone F., et al. C252 treatment relevant immunophenotyping of 139 Salivary Gland Carcinoma (SGCs). AACR-NCI-EORTC international conference on molecular targets and cancer therapeuticc 2005.
18. Dahse R., Driemel O., Schwarz S., et al. Epidermal growth factor receptor kinase domain mutations are rare in salivary gland carcinomas. Br J Cancer 2009, 100:623-625.
19. Locati L.D., Bossi P., Lo Vullo S., et al. Prognostic role of epidermal growth factor receptors 1 & 2, androgen receptor and kit in 111 salivary gland cancer. 7th international conference on head & neck cancer 2008, S067.
20. Ettl T., Schwarz S., Kleinsasser N., et al. Overexpression of EGFR and absence of C-KIT expression correlate with poor prognosis in salivary gland carcinomas. Histopathology 2008, 53:567-577.
21. Skalova A., Starek I., Vanecek T., et al. Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry. Histopathology 2003, 42:348-356.
22. Dagrada G.P., Negri T., Tamborini E., Pierotti M.A., Pilotti S. Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry. Histopathology 2004, 44:301-302.
23. Press M.F., Pike M.C., Hung G., et al. Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res 1994, 54:5675-5682.
24. Andreadis D., Epivatianos A., Poulopoulos A., et al. Detection of C-KIT (CD117) molecule in benign and malignant salivary gland tumours. Oral Oncol 2006, 42:57-65.
25. Chandan V.S., Wilbur D., Faquin W.C., Khurana K.K. Is c-kit (CD117) immunolocalization in cell block preparations useful in the differentiation of adenoid cystic carcinoma from pleomorphic adenoma?. Cancer 2004, 102:207-209.
26. Holst V.A., Marshall C.E., Moskaluk C.A., Frierson H.F. KIT protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma. Mod Pathol 1999, 12:956-960.
27. Jeng Y.M., Lin C.Y., Hsu H.C. Expression of the c-kit protein is associated with certain subtypes of salivary gland carcinoma. Cancer Lett 2000, 154:107-111.
28. Sorensen K.B., Godballe C., de S.K., Krogdahl A. Parotid carcinoma: expression of kit protein and epidermal growth factor receptor. J Oral Pathol Med 2006, 35:286-291.
29. Glas A.S., Hollema H., Nap R.E., Plukker J.T. Expression of estrogen receptor, progesterone receptor, and insulin-like growth factor receptor-1 and of MIB-1 in patients with recurrent pleomorphic adenoma of the parotid gland. Cancer 2002, 94:2211-2216.
30. Penner C.R., Folpe A.L., Budnick S.D. C-kit expression distinguishes salivary gland adenoid cystic carcinoma from polymorphous low-grade adenocarcinoma. Mod Pathol 2002, 15:687-691.
31. Edwards P.C., Bhuiya T., Kelsch R.D. C-kit expression in the salivary gland neoplasms adenoid cystic carcinoma, polymorphous low-grade adenocarcinoma, and monomorphic adenoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003, 95:586-593.
32. Vered M., Braunstein E., Buchner A. Immunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin. Head Neck 2002, 24:632-636.
33. Glisson B., Colevas A.D., Haddad R., et al. HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin Cancer Res 2004, 10:944-946.
34. Nasser S.M., Faquin W.C., Dayal Y. Expression of androgen, estrogen, and progesterone receptors in salivary gland tumors. Frequent expression of androgen receptor in a subset of malignant salivary gland tumors. Am J Clin Pathol 2003, 119:801-806.
35. Moriki T., Ueta S., Takahashi T., Mitani M., Ichien M. Salivary duct carcinoma: cytologic characteristics and application of androgen receptor immunostaining for diagnosis. Cancer 2001, 93:344-350.
36. Andersen L.J., Therkildsen M.H., Ockelmann H.H., et al. Malignant epithelial tumors in the minor salivary glands, the submandibular gland, and the sublingual gland. Prognostic factors and treatment results. Cancer 1991, 68:2431-2437.
37. Tumors of the salivary glands. AFIP atlas of tumor pathology, 4th series, fascicle 9 2008, ARP Press, Silver Spring, MD. G.L. Ellis, P.L. Auclair (Eds.).
38. Hocwald E., Yoo G.H., Adsay V., et al. Prognostic factors in major salivary gland cancer. Laryngoscope 2001, 111:1434-1439.
39. Lima R.A., Tavares M.R., Dias F.L., et al. Clinical prognostic factors in malignant parotid gland tumors. Otolaryngol Head Neck Surg 2005, 133:702-708.
40. Tumours of the head and neck. Clinical and pathological considerations 1982, Williams & Wilkins, Baltimore/London. 2nd ed. J.G. Batsakis (Ed.).
41. Waldron C.A., el-Mofty S.K., Gnepp D.R. Tumors of the intraoral minor salivary glands: a demographic and histologic study of 426 cases. Oral Surg Oral Med Oral Pathol 1988, 66:323-333.
42. Lopes M.A., Kowalski L.P., da Cunha S.G., Paes de A.O. A clinicopathologic study of 196 intraoral minor salivary gland tumours. J Oral Pathol Med 1999, 28:264-267.
43. Kress E., Schulz H.G., Neumann T. Diagnosis of diseases of the large salivary glands of the head by ultrasound, sialography and CT-sialography: a comparison of methods. HNO 1993, 345-351. [German].
44. Kurabayashi T., Ida M., Ohbayashi N., Ishii J., Sasaki T. Criteria for differentiating superficial from deep lobe tumours of the parotid gland by computed tomography. Dentomaxillofac Radiol 1993, 22:81-85.
45. Traxler M., Schurawitzki H., Ulm C., et al. Sonography of nonneoplastic disorders of the salivary glands. Int J Oral Maxillofac Surg 1992, 21:360-363.
46. Spiro R.H. Changing trends in the management of salivary tumors. Semin Surg Oncol 1995, 11:240-245.
47. Casselman J.W., Mancuso A.A. Major salivary gland masses: comparison of MR imaging and CT. Radiology 1987, 165:183-189.
48. Byrne M.N., Spector J.G., Garvin C.F., Gado M.H. Preoperative assessment of parotid masses: a comparative evaluation of radiologic techniques to histopathologic diagnosis. Laryngoscope 1989, 99:284-292.
49. Weber A.L. Imaging of the salivary glands. Curr Opin Radiol 1992, 4:117-122.
50. Renehan A., Gleave E.N., Hancock B.D., Smith P., McGurk M. Long-term follow-up of over 1000 patients with salivary gland tumours treated in a single centre. Br J Surg 1996, 83:1750-1754.
51. Gal R. Fine needle aspiration of the salivary glands: a review. Oper Tech Otolaryngol Head Neck Surg 1996, 7:323-326.
52. Riley N., Allison R., Stevenson S. Fine-needle aspiration cytology in parotid masses: our experience in Canterbury, New Zealand. ANZ J Surg 2005, 75:144-146.
53. Ellis G.L., Auclair P.L. Tumors of the salivary glands, atlas of tumor pathology, 3rd series, fascicle 17 1996, Armed Forces Institute of Pathology, Washington, DC, p. 135-6.
54. Guzzo M., Ferrari A., Marcon I., et al. Salivary gland neoplasms in children: the experience of the Istituto Nazionale Tumori of Milan. Pediatr Blood Cancer 2006, 47:806-810.
55. Gnepp D.R., Brandwein M.S., Henley J.D. Salivary and lacrimal glands. Diagnostic surgical pathology of head and neck 2001, 408. Saunders, Philadelphia. D.R. Gnepp (Ed.).
56. UICC UICC (International Union Against Cancer). TNM classification of malignant tumours 2002, Wiley-Liss, New York, Chichester, Weinheim, Brisbane, Singapore, Toronto. 6th ed. L.H. Sobin, Wittekind Ch (Eds.).
57. Cermik T.F., Mavi A., Acikgoz G., et al. FDG PET in detecting primary and recurrent malignant salivary gland tumors. Clin Nucl Med 2007, 32:286-291.
58. Jackel M.C., Reischl A., Huppert P. Efficacy of radiologic screening for distant metastases and second primaries in newly diagnosed patients with head and neck cancer. Laryngoscope 2007, 117:242-247.
59. Chen I., Tu H. Pleomorphic adenoma of the parotid gland metastasizing to the cervical lymph node. Otolaryngol Head Neck Surg 2000, 122:455-457.
60. Castle J.T., Thompson L.D., Frommelt R.A., Wenig B.M., Kessler H.P. Polymorphous low grade adenocarcinoma: a clinicopathologic study of 164 cases. Cancer 1999, 86:207-219.
61. Evans H.L., Luna M.A. Polymorphous low-grade adenocarcinoma: a study of 40 cases with long-term follow up and an evaluation of the importance of papillary areas. Am J Surg Pathol 2000, 24:1319-1328.
62. Witt R.L. Major salivary gland cancer. Surg Oncol Clin N Am 2004, 13:113-127.
63. Hickman R.E., Cawson R.A., Duffy S.W. The prognosis of specific types of salivary gland tumors. Cancer 1984, 54:1620-1624.
64. Guzzo M., Andreola S., Sirizzotti G., Cantu G. Mucoepidermoid carcinoma of the salivary glands: clinicopathologic review of 108 patients treated at the National Cancer Institute of Milan. Ann Surg Oncol 2002, 9:688-695.
65. Clode A.L., Fonseca I., Santos J.R., Soares J. Mucoepidermoid carcinoma of the salivary glands: a reappraisal of the influence of tumor differentiation on prognosis. J Surg Oncol 1991, 46:100-106.
66. Nagao T., Sugano I., Ishida Y., et al. Salivary gland malignant myoepithelioma: a clinicopathologic and immunohistochemical study of ten cases. Cancer 1998, 83:1292-1299.
67. Di Palma S., Guzzo M. Malignant myoepithelioma of salivary glands: clinicopathological features of ten cases. Virchows Arch A Pathol Anat Histopathol 1993, 423:389-396.
68. Hamper K., Lazar F., Dietel M., et al. Prognostic factors for adenoid cystic carcinoma of the head and neck: a retrospective evaluation of 96 cases. J Oral Pathol Med 1990, 19:101-107.
69. Perzin K.H., Gullane P., Clairmont A.C. Adenoid cystic carcinomas arising in salivary glands: a correlation of histologic features and clinical course. Cancer 1978, 42:265-282.
70. Tortoledo M.E., Luna M.A., Batsakis J.G. Carcinomas ex pleomorphic adenoma and malignant mixed tumors. Histomorphologic indexes. Arch Otolaryngol 1984, 110:172-176.
71. Lewis J.E., Olsen K.D., Sebo T.J. Carcinoma ex pleomorphic adenoma: pathologic analysis of 73 cases. Hum Pathol 2001, 32:596-604.
72. Guzzo M., Di Palma S., Grandi C., Molinari R. Salivary duct carcinoma: clinical characteristics and treatment strategies. Head Neck 1997, 19:126-133.
73. Barnes L., Rao U., Krause J., et al. Salivary duct carcinoma. Part I. A clinicopathologic evaluation and DNA image analysis of 13 cases with review of the literature. Oral Surg Oral Med Oral Pathol 1994, 78:64-73.
74. Bhattacharyya N., Fried M.P. Nodal metastasis in major salivary gland cancer: predictive factors and effects on survival. Arch Otolaryngol Head Neck Surg 2002, 128:904-908.
75. Frankenthaler R.A., Luna M.A., Lee S.S., et al. Prognostic variables in parotid gland cancer. Arch Otolaryngol-Head Neck Surg 1991, 117:1251-1256.
76. Spiro R.H., Huvos A.G. Stage means more than grade in adenoid cystic carcinoma. Am J Surg 1992, 164:623-628.
77. Carrillo J.F., Vazquez R., Ramirez-Ortega M.C., et al. Multivariate prediction of the probability of recurrence in patients with carcinoma of the parotid gland. Cancer 2007, 109:2043-2051.
78. Chen A.M., Garcia J., Lee N.Y., Bucci M.K., Eisele D.W. Patterns of nodal relapse after surgery and postoperative radiation therapy for carcinomas of the major and minor salivary glands: what is the role of elective neck irradiation?. Int J Radiat Oncol Biol Phys 2007, 67:988-994.
79. Fordice J., Kershaw C., El-Naggar A., Goepfert H. Adenoid cystic carcinoma of the head and neck: predictors of morbidity and mortality. Arch Otolaryngol Head Neck Surg 1999, 125:149-152.
80. Triantafillidou K., Dimitrakopoulos J., Iordanidis F., Koufogiannis D. Management of adenoid cystic carcinoma of minor salivary glands. J Oral Maxillofac Surg 2006, 64:1114-1120.
81. Seethala R.R., Barnes E.L., Hunt J.L. Epithelial-myoepithelial carcinoma: a review of the clinicopathologic spectrum and immunophenotypic characteristics in 61 tumors of the salivary glands and upper aerodigestive tract. Am J Surg Pathol 2007, 31:44-57.
82. Strick M.J., Kelly C., Soames J.V., McLean N.R. Malignant tumours of the minor salivary glands-a 20 year review. Br J Plast Surg 2004, 57:624-631.
83. Roh J.L., Kim H.S., Park C.I. Randomized clinical trial comparing partial parotidectomy versus superficial or total parotidectomy. Br J Surg 2007, 94:1081-1087.
84. Leverstein H., van der Wal J.E., Tiwari R.M., van dW I., Snow G.B. Surgical management of 246 previously untreated pleomorphic adenomas of the parotid gland. Br J Surg 1997, 84:399-403.
85. Weber R.S., Byers R.M., Petit B., et al. Submandibular gland tumors. Adverse histologic factors and therapeutic implications. Arch Otolaryngol Head Neck Surg 1990, 116:1055-1060.
86. Stennert E., Kisner D., Jungehuelsing M., et al. High incidence of lymph node metastasis in major salivary gland cancer. Arch Otolaryngol Head Neck Surg 2003, 129:720-723.
87. Scianna J.M., Petruzzelli G.J. Contemporary management of tumors of the salivary glands. Curr Oncol Rep 2007, 9:134-138.
88. Bell R.B., Dierks E.J., Homer L., Potter B.E. Management and outcome of patients with malignant salivary gland tumors. J Oral Maxillofac Surg 2005, 63:917-928.
89. Armstrong J.G., Harrison L.B., Thaler H.T., et al. The indications for elective treatment of the neck in cancer of the major salivary glands. Cancer 1992, 69:615-619.
90. Ferlito A., Shaha A.R., Rinaldo A., Mondin V. Management of clinically negative cervical lymph nodes in patients with malignant neoplasms of the parotid gland. ORL J Otorhinolaryngol Relat Spec 2001, 63:123-126.
91. Ferlito A., Shaha A.R., Rinaldo A. Surgical management of head and neck cancer: the next decade. Acta Otolaryngol 2001, 121:772-776.
92. Gavilan C., Gavilan J. Five-year results of functional neck dissection for cancer of the larynx. Arch Otolaryngol Head Neck Surg 1989, 115:1193-1196.
93. Lingeman R.E., Helmus C., Stephens R., Ulm J. Neck dissection: radical or conservative. Ann Otol Rhinol Laryngol 1977, 86:737-744.
94. Molinari R., Cantu G., Chiesa F., Grandi C. Retrospective comparison of conservative and radical neck dissection in laryngeal cancer. Ann Otol Rhinol Laryngol 1980, 89:578-581.
95. Borthne A., Kjellevold K., Kaalhus O., Vermund H. Salivary gland malignant neoplasms: treatment and prognosis. Int J Radiat Oncol Biol Phys 1986, 12:747-754.
96. Elkon D., Colman M., Hendrickson F.R. Radiation therapy in the treatment of malignant salivary gland tumors. Cancer 1978, 41:502-506.
97. Fitzpatrick P.J., Theriault C. Malignant salivary gland tumors. Int J Radiat Oncol Biol Phys 1986, 12:1743-1747.
98. Harrison L.B., Armstrong J.G., Spiro R.H., Fass D.E., Strong E.W. Postoperative radiation therapy for major salivary gland malignancies. J Surg Oncol 1990, 45:52-55.
99. McNaney D., McNeese M.D., Guillamondegui O.M., Fletcher G.H., Oswald M.J. Postoperative irradiation in malignant epithelial tumors of the parotid. Int J Radiat Oncol Biol Phys 1983, 9:1289-1295.
100. North C.A., Lee D.J., Piantadosi S., Zahurak M., Johns M.E. Carcinoma of the major salivary glands treated by surgery or surgery plus postoperative radiotherapy. Int J Radiat Oncol Biol Phys 1990, 18:1319-1326.
101. Catterall M., Errington R.D. The implications of improved treatment of malignant salivary gland tumors by fast neutron radiotherapy. Int J Radiat Oncol Biol Phys 1987, 13:1313-1318.
102. Douglas J.G., Laramore G.E., Austin-Seymour M., et al. Neutron radiotherapy for adenoid cystic carcinoma of minor salivary glands. Int J Radiat Oncol Biol Phys 1996, 36:87-93.
103. Garden A.S., Weber R.S., Ang K.K., et al. Postoperative radiation therapy for malignant tumors of minor salivary glands, outcome and patterns of failure. Cancer 1994, 73:2563-2569.
104. Garden A.S., El-Naggar A.K., Morrison W.H., et al. Postoperative radiotherapy for malignant tumors of the parotid gland. Int J Radiat Oncol Biol Phys 1997, 37:79-85.
105. Griffin B.R., Laramore G.E., Russell K.J., Griffin T.W., Eenmaa J. Fast neutron radiotherapy for advanced malignant salivary gland tumors. Radiother Oncol 1988, 12:105-111.
106. Griffin T.W., Pajak T.F., Laramore G.E., et al. Neutron vs photon irradiation of inoperable salivary gland tumors: results of an RTOG-MRC cooperative randomized study. Int J Radiat Oncol Biol Phys 1988, 15:1085-1090.
107. Krull A., Schwarz R., Heyer D., Timm H., Schmidt R. Results of neutron therapy in recurrent malignant salivary gland tumors in the head and neck area. Strahlenther Onkol 1995, 171:265-271.
108. Saroja K.R., Mansell J., Hendrickson F.R., Cohen L., Lennox A. An update on malignant salivary gland tumors treated with neutrons at Fermilab. Int J Radiat Oncol Biol Phys 1987, 13:1319-1325.
109. Sessions R.B., Lehane D.E., Smith R.J., Bryan R.N., Suen J.Y. Intra-arterial cisplatin treatment of adenoid cystic carcinoma. Arch Otolaryngol 1982, 108:221-224.
110. Stelzer K.J., Laramore G.E., Griffin T.W., et al. Fast neutron radiotherapy. The University of Washington experience. Acta Oncol 1994, 33:275-280.
111. Terhaard C.H., Lubsen H., Van dT I., et al. Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck oncology cooperative group. Head Neck 2004, 26:681-692.
112. Neutron versus photon irradiation for unresectable salivary gland tumors: final report of an RTOG-MRC randomized clinical trial. Medical Research Council. Int J Radiat Oncol Biol Phys 1993, 27:235-240. Radiation Therapy Oncology Group.
113. Douglas J.G., Koh W.J., Austin-Seymour M., Laramore G.E. Treatment of salivary gland neoplasms with fast neutron radiotherapy. Arch Otolaryngol Head Neck Surg 2003, 129:944-948.
114. Bittner N., Koh W.J., Laramore G.E., et al. Treatment of locally advanced adenoid cystic carcinoma of the trachea with neutron radiotherapy. Int J Radiat Oncol Biol Phys 2008, 72:410-414.
115. Schulz-Ertner D., Nikoghosyan A., Didinger B., et al. Therapy strategies for locally advanced adenoid cystic carcinomas using modern radiation therapy techniques. Cancer 2005, 104:338-344.
116. Barnett T.A., Kapp D.S., Goffinet D.R. Adenoid cystic carcinoma of the salivary glands. Management of recurrent, advanced, or persistent disease with hyperthermia and radiation therapy. Cancer 1990, 65:2648-2656.
117. Gabriele P., Amichetti M., Orecchia R., Valdagni R. Hyperthermia and radiation therapy for inoperable or recurrent parotid carcinoma. A phase I/II study. Cancer 1995, 75:908-913.
118. Locati L.D., Guzzo M., Bossi P., et al. Lung metastasectomy in adenoid cystic carcinoma (ACC) of salivary gland. Oral Oncol 2005, 41:890-894.
119. Laurie S.A., Licitra L. Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol 2006, 24:2673-2678.
120. Airoldi M., Brando V., Giordano C., et al. Chemotherapy for recurrent salivary gland malignancies: experience of the ENT Department of Turin University. ORL J Oto-Rhino-Laryngol Relat Spec 1994, 56:105-111.
121. Alberts D.S., Manning M.R., Coulthard S.W., Koopmann C.F.J., Herman T.S. Adriamycin/cis-platinum/cyclophosphamide combination chemotherapy for advanced carcinoma of the parotid gland. Cancer 1981, 47:645-648.
122. Belani C.P., Eisenberger M.A., Gray W.C. Preliminary experience with chemotherapy in advanced salivary gland neoplasms. Med Pediatr Oncol 1988, 16:197-202.
123. Creagan E.T., Woods J.E., Rubin J., Schaid D.J. Cisplatin-based chemotherapy for neoplasms arising from salivary glands and contiguous structures in the head and neck. Cancer 1988, 62:2313-2319.
124. Dimery I.W., Legha S.S., Shirinian M., Hong W.K. Fluorouracil, doxorubicin, cyclophosphamide, and cysplatin combination chemotherapy in advanced or recurrent salivary gland carcinoma. J Clin Oncol 1990, 8:1056-1062.
125. Jones A.S., Phillips D.E., Cook J.A., Helliwell T.R. A randomised phase II trial of epirubicin and 5-fluorouracil versus cisplatinum in the palliation of advanced and recurrent malignant tumour of the salivary glands. Br J Cancer 1993, 67:112-114.
126. Licitra L., Marchini S., Spinazze S., et al. Cisplatin in advanced salivary gland carcinoma. A phase II sudy of 25 patients. Cancer 1991, 68:1874-1877.
127. Licitra L., Cavina R., Grandi C., et al. Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients. Ann Oncol 1996, 7:640-642.
128. Posner M.R., Ervin T.J., Weichselbaum R.R., Fabian R.L., Miller D. Chemotherapy of advanced salivary gland neoplasms. Cancer 1982, 50:2261-2264.
129. Schramm V.L.J., Srodes C., Myers E.N. Cisplatin therapy for adenoid cystic carcinoma. Arch Otolaryngol 1981, 107:739-741.
130. Triozzi P.L., Brantley A., Fisher S., et al. 5-Fluorouracil, cyclophosphamide, and vincristine for adenoid cystic carcinoma of the head and neck. Cancer 1987, 59:887-890.
131. Venook A.P., Tseng A.J., Meyers F.J., et al. Cisplatin, doxorubicin, and 5-fluorouracil chemotherapy for salivary gland malignancies: a pilot study of the Northern California Oncology Group. J Clin Oncol 1987, 5:951-955.
132. Kaplan M.J., Johns M.E., Cantrell R.W. Chemotherapy for salivary gland cancer. Otolaryngol Head Neck Surg 1986, 95:165-170.
133. Gilbert J., Li Y., Pinto H.A., et al. Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group. Head Neck 2006, 28:197-204.
134. van Herpen C.M., Locati L.D., Buter J., et al. Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982). Eur J Cancer 2008, 44:2542-2545.
135. Hotte S.J., Winquist E.W., Lamont E., et al. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol 2005, 23:585-590.
136. Glisson B.S., Blumenschein G., Francisco M., et al. Phase II trial of gefitinib in patients with incurable salivary gland cancer. ASCO Annual Meeting Proceedings, vol. 23 2005, 508s.
137. Locati L.D., Bossi P., Perrone F., et al. Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a phase II study. Oral Oncol 2009, 45:574-578.
138. Agulnik M., Cohen E.W., Cohen R.B., et al. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol 2007, 25:3978-3984.
139. Haddad R., Colevas A.D., Krane J.F., et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol 2003, 39:724-727.
140. Alcedo J.C., Fabrega J.M., Arosemena J.R., Urrutia A. Imatinib mesylate as treatment for adenoid cystic carcinoma of the salivary glands: report of two successfully treated cases. Head Neck 2004, 26:829-831.
141. Faivre S., Raymond E., Casiraghi O., Temam S., Berthaud P. Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands. J Clin Oncol 2005, 23:6271-6273.
142. Argiris A., Goldwasser M.A., Burtness B., et al. A phase II trial of PS-341 (bortezomib) followed by the addition of doxorubicin at progression in incurable adenoid cystic carcinoma of the head and neck: An Eastern Cooperative Oncology Group study. J Clin Oncol 2006, 5573.
143. Rugo H.S., Herbst R.S., Liu G., et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 2005, 23:5474-5483.
144. Helmus C. Subtotal parotidectomy: a 10-year review (1985-1994). Laryngoscope 1997, 107:1024-1027.
145. Stevens K.L., Hobsley M. The treatment of pleomorphic adenomas by formal parotidectomy. Br J Surg 1982, 69:1-3.
146. Myssiorek D., Ruah C.B., Hybels R.L. Recurrent pleomorphic adenomas of the parotid gland. Head Neck 1990, 12:332-336.
147. Simpson J.R. Cancer of the salivary glands. Radiation oncology 1987, 513-528. Lippincott, Philadelphia. C.A. Perez, L.W. Brady (Eds.).
148. McNeese M.D., Fletcher G.H. Tumors of the major and minor salivary glands. Radiation therapy of head and neck cancer 1989, Springer-Verlag, Berlin, Heidelberg, New York, London, Pris, Tokyo, p. 181-96.
149. Moss W.T. The salivary glands. Moss' radiation oncology: rationale, technique, results 1994, Mosby, p. 121-31. 7th ed.